C.M. Bidwell & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

C.M. Bidwell & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-201	Closed	-$119K	–	530
2022 Q2	$119K	Hold	201	–	–	0.09%	195
2022 Q1	$140K	Sell	201 -252	-56%	-$159K	0.09%	201
2021 Q4	$286K	Buy	453 +252	+125%	+$155K	0.18%	102
2021 Q3	$122K	Buy	+201	New	+$125K	0.08%	229
2021 Q1	–	Sell	-156	Closed	-$75K	–	544
2020 Q4	$75K	Sell	156 -359	-70%	-$194K	0.06%	256
2020 Q3	$288K	Sell	515 -155	-23%	-$94K	0.27%	66
2020 Q2	$418K	Buy	670 +461	+221%	+$262K	0.38%	46
2020 Q1	$102K	Buy	+209	New	+$86.2K	0.11%	168
2019 Q2	–	Sell	-520	Closed	-$214K	–	445
2019 Q1	$214K	Sell	520 -15	-3%	-$6.18K	0.21%	123
2018 Q4	$200K	Buy	+535	New	+$196K	0.22%	126
2018 Q2	–	Sell	-1,050	Closed	-$362K	–	444
2018 Q1	$362K	Buy	1,050 +50	+5%	+$17.4K	0.33%	83
2017 Q4	$376K	Buy	+1,000	New	+$405K	0.32%	92
2016 Q4	–	Sell	-10,020	Closed	-$4.03M	–	295
2016 Q3	$4.03M	Hold	10,020	–	–	0.96%	39
2016 Q2	$3.5M	Hold	10,020	–	–	0.87%	70
2016 Q1	$3.61M	Buy	+10,020	New	+$4.13M	0.9%	62

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

C.M. Bidwell & Associates's REGN Position: Q3 2022 in Review

C.M. Bidwell & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 201 shares — an estimated $119K sold.

C.M. Bidwell & Associates first reported a position in REGN in Q1 2016 and held it in 15 quarters. The position peaked at $4.03M in Q3 2016. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

C.M. Bidwell & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
C.M. Bidwell & Associates sold 201 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $119K.
C.M. Bidwell & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 15 quarters.
C.M. Bidwell & Associates's Regeneron Pharmaceuticals position peaked at $4.03M in Q3 2016.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2022, filed 14 Nov 2022.